-
公开(公告)号：EP1071751A1
公开(公告)日：2001-01-31
申请号：EP99918586.1
申请日：1999-04-15
IPC分类号： C12N5/10 , A01K67/027 , C07K14/705 , A61K49/00
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2217/072 , A01K2227/105 , A01K2267/03 , C07K14/70557 , C12N2800/30
摘要： The present invention relates to mammals into which foreign DNA has been introduced or in which various modifications or substitutions have been made to an integrin β subunit, thereby generating transgenic or genetically-engineered non-human mammals. In particular, the present invention provides a transgenic mammal in which the endogenous GP IIIa gene has been replaced with an altered or mutant GP IIIa gene in which one or all of the phosphorylatable cytoplasmic tyrosine residues have been replaced with non-tyrosine residues such as phenylalanine. Since the platelets in the blood of the resultant transgenic mammals expressing the altered or mutant GP IIIa cannot undergo tyrosine phosphorylation to the extent that it occurs in wild-type mammals, these genetically-engineered animals provide a critical tool for assessing the importance of the phosphorylation reaction for platelet function. The invention is also useful for studying the effect of the mutant GP IIIa integrin subunit on biological processes other than platelet formation.
-
公开(公告)号：EP0942931A2
公开(公告)日：1999-09-22
申请号：EP97952309.0
申请日：1997-11-21
CPC分类号： C07K14/70546 , A61K38/00 , C07K14/70557
摘要： The present invention describes a direct interaction between myosin and the cytoplasmic domain of membrane proteins, particularly the phosphorylated cytoplasmic domains of the β-subunit of integrins. The invention provides methods of identifying agents which block integrin binding to myosin, methods of using agents which block integrin binding to myosin to modulate biological and pathological processes, and provides agents that block integrin mediated binding to myosin and thereby modulate related cellular or cellular component movement.
-
3.发明公开IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION 失效IDENTIFYING BAP-1，即整关系和整合素介导SIGNALUEBERTRAGUNG涉及到蛋白质
公开(公告)号：EP0939815A1
公开(公告)日：1999-09-08
申请号：EP97949458.0
申请日：1997-11-18
发明人： LI, Shengfeng , PHILLIPS, David, R.
IPC分类号： G01N33 , A61K45 , A61P7 , A61P29 , A61P35 , C07K14 , C07K16 , C07K17 , C12N1 , C12N5 , C12N15 , C12P21 , C12Q1 , A61K38
摘要： The present invention provides the amino acid and nucleotide sequence of a protein that binds to β3 integrins, αIIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.
-
公开(公告)号：EP1102840A2
公开(公告)日：2001-05-30
申请号：EP99941999.7
申请日：1999-08-04
IPC分类号： C12N15/00 , A01K67/027 , C12N15/12 , C07K14/705 , C12N5/10 , A61K49/00
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0381 , C07K14/705
摘要： The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of GP V, including the screening and identification of potential therapeutic agents.
-
公开(公告)号：EP0422125B1
公开(公告)日：1996-10-23
申请号：EP89908344.8
申请日：1989-06-30
CPC分类号： C07K14/70557 , A61K38/00 , C07K2319/00 , C07K2319/33 , Y10S530/806
摘要： Methods and compositions are provided for treating platelet-associated ischemic syndromes utilizing oligopeptides corresponding to regions of the platelet GPIIIa protein. The oligopeptides can be used to block platelet aggregation for numerous applications, and can serve in immunogen to raise receptor-specific antibodies.
-
公开(公告)号：EP0707648A1
公开(公告)日：1996-04-24
申请号：EP94923370.0
申请日：1994-07-07
IPC分类号： G01N33 , A61K38 , A61K39 , A61P7 , C07H21 , C07K14 , C07K16 , C12N1 , C12N5 , C12N15 , C12Q1
CPC分类号： C07K14/705 , A61K38/00
摘要： This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.
-
公开(公告)号：EP0422125A1
公开(公告)日：1991-04-17
申请号：EP89908344.0
申请日：1989-06-30
IPC分类号： G01N33 , A61K9 , A61K38 , A61K39 , A61K51 , A61P7 , C07K7 , C07K14 , C07K16 , C07K19 , C12N15 , C12P21 , C12R1
CPC分类号： C07K14/70557 , A61K38/00 , C07K2319/00 , C07K2319/33 , Y10S530/806
摘要： On a mis au point des procédés et des compositions permettant de traiter des syndromes ischémiques associés aux plaquettes, utilisant des oligopeptides correspondant aux régions de la protéine GPIIIa des plaquettes. On peut utiliser les oligopeptides pour bloquer l'agrégation de plaquettes dans de nombreuses applications. Ils peuvent également servir dans des immunogènes pour augmenter le nombre d'anticorps spécifiques de récepteurs.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.014 秒)
